Cognitive impairment following hormone therapy: Current opinion of research in breast and prostate cancer patients

Lisa M. Wu, Ali Amidi*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Purpose of review Hormone therapy is a common cancer treatment that may be associated with numerous side and late effects, and in recent years, has been linked to changes in cognition. Here, we present the most important recent findings from empirical studies and reviews that have focused on the effects of hormone therapy on cognitive functioning in breast and prostate cancer populations, underline some general shortcomings, and propose directions for future research. Recent findings Recent research indicates that cognitive impairment may occur in breast and prostate cancer patients following onset of hormone therapy. However, because of methodological shortcomings and heterogeneity of current research, conclusions regarding the effects of hormone therapy on cognitive functions remain tentative. Summary The review highlights the general findings while also describing the many methodological shortcomings that need to be addressed in future research. It is clear that larger scale neuropsychological studies that also evaluate the impact of impairments on daily life functioning will improve our understanding of the effects of hormone therapy on cognition and inform the development of appropriate interventions.

Original languageEnglish (US)
Pages (from-to)38-45
Number of pages8
JournalCurrent opinion in supportive and palliative care
Volume11
Issue number1
DOIs
StatePublished - Mar 1 2017

Keywords

  • androgen deprivation therapy
  • cancer
  • cognitive impairment
  • endocrine therapy
  • hormone therapy

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Cognitive impairment following hormone therapy: Current opinion of research in breast and prostate cancer patients'. Together they form a unique fingerprint.

Cite this